Antiarrhythmic drug therapy (Part 2). Benefits and hazards.
D000638:Amiodarone / Q000009:adverse effects / Q000627:therapeutic use; D000813:Anilides / Q000009:adverse effects / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000139:chemically induced / Q000188:drug therapy*; D044482:Benzeneacetamides; D016700:Encainide; D005424:Flecainide; D006801:Humans; D008012:Lidocaine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D008801:Mexiletine / Q000009:adverse effects / Q000627:therapeutic use; D016293:Moricizine; D010640:Phenothiazines / Q000009:adverse effects / Q000627:therapeutic use; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use; D011405:Propafenone; D011427:Propiophenones / Q000009:adverse effects / Q000627:therapeutic use; D016677:Tocainide
D000813:Anilides; D000889:Anti-Arrhythmia Agents; D044482:Benzeneacetamides; D010640:Phenothiazines; D010880:Piperidines; D011427:Propiophenones; D008801:Mexiletine; D016677:Tocainide; D016293:Moricizine; D011405:Propafenone; D008012:Lidocaine; D005424:Flecainide; C015970:lorcainide; D000638:Amiodarone; D016700:Encainide